Investigational Drugs
Investigational drugs for NAFLD are derived from global clinical trials with the latest progress, and detailed drug properties are extracted from DrugBank and PubChem. For each drug, related therapeutic strategies, targets, and clinical trials in NAFLDkb are presented with knowledge graphs.
stats1
stats2
Search for:
Lipid metabolism46 records.
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D013 | Aramchol | Chemical drug | DB11860 | SCD-1 | Enhance lipid metabolism | Under clinical trials | Details |
| D018 | Aspirin | Chemical drug | DB00945 | AKR1C1 inhibitor; PCNA downregulator | Enhance lipid metabolism | Under clinical trials | Details |
| D020 | Atorvastatin | Chemical drug | DB01076 | DPP4 inhibitor; AHR agonist; HDAC2 inhibitor; NR1I3 ligand | Enhance lipid metabolism | Under clinical trials | Details |
| D030 | Bergamot | Biological drug | DB14335 | -- | Enhance lipid metabolism | Under clinical trials | Details |
| D040 | BIO89-100 | Biological drug | -- | FGF21 analog | Improve insulin resistance; Enhance lipid metabolism | Under clinical trials | Details |
| D046 | Pegbelfermin | Biological drug | DB15365 | FGF21 analog | Improve insulin resistance; Enhance lipid metabolism; Anti-fibrosis | Under clinical trials | Details |
| D062 | Carnitine complex | Supplement | DB00583 | SLC22A4; SLC22A5; CRAT; MPO | -- | Under clinical trials | Details |
| D075 | Choline | Supplement | DB00122 | PLD2 product of; PLD1 product of | -- | Under clinical trials | Details |
| D078 | Cilofexor | Chemical drug | DB15168 | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| D117 | EDP-305 | Chemical drug | -- | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| D125 | Epanova | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Enhance lipid metabolism | Under clinical trials | Details |
| D130 | EYP001a | Chemical drug | -- | FXR agonist;FXR modulator | Enhance lipid metabolism | Under clinical trials | Details |
| D131 | Ezetimibe | Chemical drug | DB00973 | SOAT1 inhibitor; | Enhance lipid metabolism | Under clinical trials | Details |
| D133 | Fenofibrate | Chemical drug | DB01039 | PPARA agonist; NR1I2 partial agonist | Anti-inflammatory | Under clinical trials | Details |
| D136 | Firsocostat | Chemical drug | DB16166 | ACC inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D143 | FT-4101 | Miscellany | -- | FASN inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D149 | Gemcabene | Chemical drug | DB05123 | ACC inhibitor; apo C-III inhibitor; CRP inhibitor; CCR2 receptor antagonist; CCR5 receptor antagonist; lipoprotein A inhibitor; PPAR agonist; sulfatase inhibitor | Enhance lipid metabolism; Anti-fibrosis | Failed in clinical trials | Details |
| D184 | INT-767 | Chemical drug | -- | FXR agonist; TGR5 agonist | Enhance lipid metabolism | Under investigation | Details |
| D186 | ION 224 | Miscellany | -- | DGAT2 inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D201 | L-Carnitine | Supplement | DB00583 | SLC22A4; SLC22A5; CRAT; MPO | -- | Under clinical trials | Details |
| D203 | Levothyroxine | Chemical drug | DB00451 | THRA agonist; THRB agonist | Anti-fibrosis | Under clinical trials | Details |
| D241 | Nidufexor | Chemical drug | DB16255 | FXR modulator | Enhance lipid metabolism | Under clinical trials | Details |
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D260 | Orlistat | Chemical drug | DB01083 | FASN inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D268 | PF-05221304 | Chemical drug | -- | ACC inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D269 | PF-06835919 | Chemical drug | -- | Ketohexokinase inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D270 | PF-06865571 | Chemical drug | -- | DGAT2 inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D277 | Pitavastatin | Chemical drug | DB08860 | HMGCR inhibitor | Enhance lipid metabolism | Failed in clinical trials | Details |
| D312 | Rosuvastatin | Chemical drug | DB01098 | HMGCR inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D360 | Telmisartan | Chemical drug | DB00966 | PPARG partial agonist | Improve insulin resistance | Under clinical trials | Details |
| D362 | TERN-101 | Chemical drug | DB16045 | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| D371 | Tocotrienol | Chemical drug | DB12647 | HMG-CoA inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D378 | Troglitazone | Chemical drug | DB00197 | PPARG agonist; PPARD; PPARA | Improve insulin resistance | Under investigation | Details |
| D379 | Tropifexor | Chemical drug | DB16343 | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| D380 | TVB-2640 | Chemical drug | -- | FASN inhibitor | Enhance lipid metabolism; Anticancer agent | Under clinical trials | Details |
| D406 | Gemfibrozil | Chemical drug | DB01241 | PPARA agonist; SLCO1B1 inhibitor; SLC22A8 inhibitor; SLCO2B1 inhibitor; SLCO1B3 inhibitor | Hypolipidemic drug | Under investigation | Details |
| D574 | ND-654 | Chemical drug | -- | Acetyl-CoA carboxylase inhibitor | Enhance lipid metabolism | Under investigation | Details |
| D575 | WZ66 | Miscellany | -- | ACC inhibitor | Enhance lipid metabolism | Under investigation | Details |
| D576 | Hydroxy citrate | Chemical drug | -- | ACLY iinhibitor | Enhance lipid metabolism | Under investigation | Details |
| D577 | Bempedoic acid | Chemical drug | -- | ACLY iinhibitor | Enhance lipid metabolism | Under investigation | Details |
| D578 | 25-HL | Miscellany | -- | SREBP inhibitor | Enhance lipid metabolism | Under investigation | Details |
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D580 | Tiliamsoine | Miscellany | -- | FXR agonist | Enhance lipid metabolism | Under investigation | Details |
| D581 | sobetirome | Chemical drug | -- | Thyroid hormone receptor beta agonists | Enhance lipid metabolism | Under investigation | Details |
| D582 | EPB-53 | Miscellany | -- | FGF21 agonist | Enhance lipid metabolism | Under investigation | Details |
| D583 | Doxorubicin | Chemical drug | -- | DNA intercalators; Type II DNA topoisomerase inhibitors | Enhance lipid metabolism | Under investigation | Details |